Christopher H. Polman

Christopher H. Polman's AcademicInfluence.com Rankings

Philosophy

#4280

World Rank

#6747

Historical Rank

Logic

#1780

World Rank

#2619

Historical Rank

philosophy Degrees

Christopher H. Polman

Biology

#5576

World Rank

#8089

Historical Rank

Neuroscience

#631

World Rank

#658

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Christopher H. Polman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christopher H. Polman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria (2011) (8941)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis (2001) (6788)
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” (2005) (5003)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. (2006) (2970)
Defining the clinical course of multiple sclerosis (2014) (2372)
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. (2010) (2329)
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. (1997) (1280)
Oral fingolimod (FTY720) for relapsing multiple sclerosis. (2006) (854)
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci (2009) (799)
Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability (1999) (731)
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 (1996) (724)
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis (1998) (645)
Differential diagnosis of suspected multiple sclerosis: a consensus approach (2008) (624)
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes (2006) (576)
T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis (2010) (547)
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study (2007) (503)
Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis (2010) (502)
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. (2005) (494)
Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis (1996) (464)
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. (2009) (464)
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study (2008) (449)
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. (2005) (442)
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study (2009) (435)
Vitamin D as an early predictor of multiple sclerosis activity and progression. (2014) (428)
EFNS guidelines on diagnosis and management of neuromyelitis optica (2010) (414)
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients (2015) (403)
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis (2009) (400)
Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. (1998) (392)
The small heat-shock protein αB-crystallin as candidate autoantigen in multiple sclerosis (1995) (388)
Diagnostic criteria for primary progressive multiple sclerosis: A position paper (2000) (383)
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial (2009) (368)
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process (2015) (346)
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study (2007) (334)
Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. (2003) (320)
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS (2007) (317)
Correlating MRI and clinical disease activity in multiple sclerosis (1995) (314)
Interferons in relapsing remitting multiple sclerosis: a systematic review (2003) (307)
Spinal cord abnormalities in recently diagnosed MS patients (2004) (299)
Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. (1998) (282)
Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. (2001) (273)
Decreased interleukin‐10 and increased interleukin‐12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis (1999) (270)
Primary progressive multiple sclerosis. (1997) (267)
Brain atrophy and lesion load predict long term disability in multiple sclerosis (2013) (265)
Circulating Vα24+ Vβ11+ NKT Cell Numbers Are Decreased in a Wide Variety of Diseases That Are Characterized by Autoreactive Tissue Damage (2001) (264)
The Brief Repeatable Battery of Neuropsychological Tests: normative values allow application in multiple sclerosis clinical practice (2001) (262)
Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS (2004) (262)
The incidence and significance of anti-natalizumab antibodies (2007) (260)
MRI criteria for MS in patients with clinically isolated syndromes (2010) (256)
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo (2009) (255)
MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation” (2006) (245)
Biological markers in CSF and blood for axonal degeneration in multiple sclerosis (2005) (244)
Multiple Sclerosis: Current Knowledge and Future Outlook (2014) (239)
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial (1997) (237)
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS (2005) (237)
Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. (2010) (236)
TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients (1997) (232)
Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. (1999) (232)
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. (2002) (219)
Postmortem verification of MS cortical lesion detection with 3D DIR (2012) (219)
Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis (2005) (218)
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects (2012) (211)
Interferon beta-1b in secondary progressive MS (2004) (207)
Information processing characteristics in subtypes of multiple sclerosis (2002) (206)
The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. (2000) (203)
Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women (2009) (201)
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis (2010) (200)
Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. (2003) (198)
Multiple sclerosis and vitamin D: an update (2004) (197)
Neuronal damage in T1‐hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy (1999) (196)
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial (2012) (194)
Health‐related quality of life in multiple sclerosis: effects of natalizumab (2007) (190)
Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. (2004) (190)
PML in a patient treated with dimethyl fumarate from a compounding pharmacy. (2013) (183)
Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. (2008) (182)
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability (2011) (180)
Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. (2002) (176)
Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. (2006) (174)
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis (2006) (165)
Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. (2002) (165)
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis (2011) (164)
Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. (2009) (162)
Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype. (2001) (161)
The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. (1995) (161)
Cognitive impairment and decline in different MS subtypes (2006) (159)
Altered diffusion tensor in multiple sclerosis normal‐appearing brain tissue: Cortical diffusion changes seem related to clinical deterioration (2006) (158)
Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. (2007) (155)
Interferon in relapsing-remitting multiple sclerosis. (2001) (153)
Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis (2010) (151)
Safety, tolerability, and efficacy of orally administered cannabinoids in MS (2002) (149)
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring (2007) (146)
POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS (2008) (146)
A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. (2009) (145)
The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results. (2004) (141)
Association of interleukin-1β and interleukin-1 receptor antagonist genes with disease severity in MS (1999) (141)
Lack of association between antimyelin antibodies and progression to multiple sclerosis. (2007) (141)
MR spectroscopic evidence for glial increase but not for neuro‐axonal damage in MS normal‐appearing white matter (2005) (140)
Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis (2005) (140)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL (2009) (139)
Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. (2013) (138)
Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS (2001) (138)
Optimizing the association between disability and biological markers in MS (2001) (138)
Spinal cord lesions in patients with clinically isolated syndrome (2013) (137)
The effect of 4‐aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo‐controlled, double‐blind, cross‐over study (1992) (137)
Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions (2002) (136)
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study (2002) (134)
No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study (2010) (134)
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study (2005) (133)
MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study (2006) (132)
4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. (1994) (132)
MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis (2006) (131)
Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis (2009) (131)
Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b (2003) (129)
Can the Expanded Disability Status Scale be assessed by telephone? (2003) (129)
Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. (2001) (127)
Elevated osteopontin levels in active relapsing‐remitting multiple sclerosis (2003) (127)
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis (2007) (127)
Primary and transitional progressive MS (1999) (126)
Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. (2001) (124)
Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis (1994) (124)
Subcortical atrophy and cognition (2012) (119)
Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients (2008) (119)
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis (2004) (118)
The Multiple Sclerosis Functional Composite (2010) (118)
Natalizumab: bench to bedside and beyond. (2013) (118)
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study (2014) (118)
MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability. (1997) (117)
Functional brain network analysis using minimum spanning trees in Multiple Sclerosis: An MEG source-space study (2014) (117)
Recombinant Interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells (1996) (114)
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis (2013) (114)
Long-term effects of fingolimod in multiple sclerosis (2015) (113)
Functional connectivity changes in multiple sclerosis patients: A graph analytical study of MEG resting state data (2013) (112)
Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patients (1999) (112)
Structural degree predicts functional network connectivity: A multimodal resting-state fMRI and MEG study (2014) (111)
Immunohistological analysis of macrophages in the central nervous system of Lewis rats with acute experimental allergic encephalomyelitis (1986) (111)
A longitudinal study of cognition in primary progressive multiple sclerosis. (2005) (110)
Cognitive impairment in MS (2013) (109)
Macrophages in the central nervous system of the rat. (1987) (108)
Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis (2011) (108)
One year follow up study of primary and transitional progressive multiple sclerosis (2000) (107)
Predicting progression in primary progressive multiple sclerosis: A 10‐year multicenter study (2008) (107)
IL-7 Promotes TH1 Development and Serum IL-7 Predicts Clinical Response to Interferon-β in Multiple Sclerosis (2011) (106)
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks (2010) (105)
Oral treatment for multiple sclerosis (2011) (104)
Production of IL-1β and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis (2002) (104)
Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis (2014) (103)
In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology (2005) (103)
Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration (2014) (103)
Prediction of anxiety and distress following diagnosis of multiple sclerosis: a two-year longitudinal study (2006) (102)
T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. (2001) (101)
Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. (1997) (98)
Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients (2003) (98)
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. (2012) (98)
A subtype of multiple sclerosis defined by an activated immune defense program (2006) (98)
Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. (2009) (97)
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis (2009) (97)
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis (2011) (96)
Multiple sclerosis (2003) (96)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL (2009) (94)
Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability (2004) (94)
Spinal-cord MRI in multiple sclerosis (2003) (93)
Cardiovascular autonomic function in multiple sclerosis (1991) (93)
Osteopontin levels and increased disease activity in relapsing–remitting multiple sclerosis patients (2004) (93)
Assessing disability progression with the Multiple Sclerosis Functional Composite (2009) (92)
Exploring differences between subgroups of multiple sclerosis patients in health-related quality of life (1999) (92)
Multiple sclerosis diagnostic criteria: three years later (2005) (92)
APOE epsilon variation in multiple sclerosis susceptibility and disease severity (2006) (89)
Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat (1988) (89)
Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla (2014) (88)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein (2012) (86)
Pain in Parkinson's disease and multiple sclerosis: Its relation to the medial and lateral pain systems (2005) (86)
Gender-related differences in functional connectivity in multiple sclerosis (2012) (85)
Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. (2009) (84)
Concurrent validity of the MS Functional Composite using MRI as a biological disease marker (2001) (84)
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT (2013) (84)
Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis (2004) (83)
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi‐centre fMRI study (2008) (83)
A dam for retrograde axonal degeneration in multiple sclerosis? (2014) (83)
Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis. (2006) (83)
Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis (1995) (83)
Comparisons of patient self-report, neurologic examination, and functional impairment in MS (2001) (83)
Functional brain networks: Linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG Study (2014) (82)
Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients (1991) (82)
The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS (2003) (82)
4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. (1993) (82)
Quantitative 1H‐MRS of healthy human cortex, hippocampus, and thalamus: Metabolite concentrations, quantification precision, and reproducibility (2004) (82)
Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy (2001) (80)
The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis. (1995) (80)
MS Functional Composite (2000) (80)
Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis (2003) (78)
Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR (2011) (78)
Cognitive and Clinical Dysfunction, Altered MEG Resting-State Networks and Thalamic Atrophy in Multiple Sclerosis (2013) (78)
Disruption of structural and functional networks in long‐standing multiple sclerosis (2014) (78)
Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis (1993) (78)
Axon loss is an important determinant of weakness in multifocal motor neuropathy (2006) (78)
Microcystic macular oedema confirmed, but not specific for multiple sclerosis. (2012) (77)
Clinical correlations of brain lesion distribution in multiple sclerosis (2009) (76)
Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosis (2012) (76)
Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use (2005) (76)
MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain (2007) (75)
Quality of life during the first 6 months of interferon-b treatment in patients with MS (2000) (75)
The effects of 4‐aminopyridine on cognitive function in patients with multiple sclerosis (1994) (75)
A three-year, multi-parametric MRI study in patients at presentation with CIS (2008) (75)
Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis (2010) (75)
Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b (2008) (74)
Quality of life in multiple sclerosis: The disability and impact profile (DIP) (1996) (73)
Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria (2005) (73)
Determinants of interferon β efficacy in patients with multiple sclerosis (2011) (73)
Does high-field MR imaging improve cortical lesion detection in multiple sclerosis? (2008) (73)
Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter (2013) (72)
Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials (2000) (72)
Multiple sclerosis patients show a highly significant decrease in alpha band interhemispheric synchronization measured using MEG (2006) (72)
Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity. (1999) (71)
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS (2012) (71)
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials (2012) (71)
Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis (2014) (71)
Glutamate inhibition in MS: The neuroprotective properties of riluzole (2005) (71)
Predictors of relapse rate in MS clinical trials (2005) (70)
Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated (2010) (70)
Drug treatment of multiple sclerosis (2000) (69)
Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction (2006) (69)
Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis (1994) (69)
Sex‐specific extent and severity of white matter damage in multiple sclerosis: Implications for cognitive decline (2014) (68)
The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MS (2001) (66)
Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data (2011) (66)
Clinical–MRI correlations in a European trial of interferon beta-1b in secondary progressive MS (2001) (66)
Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosis (2014) (65)
Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional C omposite (2004) (65)
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study (2012) (65)
Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis (2014) (64)
The Genetic Association of Variants in CD6, TNFRSF1A and IRF8 to Multiple Sclerosis: A Multicenter Case-Control Study (2011) (64)
Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data (2005) (64)
An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis (2004) (64)
Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. (2014) (64)
New and emerging treatment options for multiple sclerosis (2003) (64)
Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis. (2005) (63)
Value of health-related quality of life to predict disability course in multiple sclerosis (2004) (63)
Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis (2012) (63)
Multicontrast MR Imaging at 7T in Multiple Sclerosis: Highest Lesion Detection in Cortical Gray Matter with 3D-FLAIR (2013) (62)
Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region (2002) (62)
Increased production of tumor necrosis factor α, and not of interferon γ, preceding disease activity in Patients with multiple sclerosis (1998) (61)
Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. (1999) (61)
Interferon-β1b in the treatment of secondary progressive MS (2001) (61)
Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis. (1995) (61)
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS (2008) (61)
Diffuse signal abnormalities in the spinal cord in multiple sclerosis: Direct postmortem in situ magnetic resonance imaging correlated with in vitro high‐resolution magnetic resonance imaging and histopathology (2002) (59)
1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease (2003) (58)
4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. (1994) (58)
Cognitive Dysfunction in Early Multiple Sclerosis: Altered Centrality Derived from Resting-State Functional Connectivity Using Magneto-Encephalography (2012) (58)
Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition (2008) (58)
Interleukin‐12p40 genotype plays a role in the susceptibility to multiple sclerosis (2001) (58)
Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters (2007) (58)
A health‐related quality of life questionnaire for multiple sclerosis Patients (1999) (57)
CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis (2007) (57)
Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease (2007) (57)
4-Aminopyridine induces functional improvement in multiple sclerosis patients: A neurophysiological study (1993) (57)
Diffusely Abnormal White Matter in Progressive Multiple Sclerosis: In Vivo Quantitative MR Imaging Characterization and Comparison between Disease Types (2010) (55)
The patient's perception of a (reliable) change in the Multiple Sclerosis Functional C omposite (2004) (55)
Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease (2001) (54)
Rapid Spontaneous Resolution of an Acute Subdural Hematoma (1986) (54)
The usefulness of evaluative outcome measures in patients with multiple sclerosis. (2006) (54)
T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis (2010) (54)
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS (2012) (54)
Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue (2002) (53)
Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis (2008) (53)
CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis (2003) (52)
Ophthalmoplegic and lower cranial nerve variants merge into each other and into classical Guillain‐Barré syndrome (1998) (52)
Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. (1997) (52)
MRI features of benign multiple sclerosis (2009) (51)
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. (2007) (51)
Two-year follow-up study of primary and transitional progressive multiple sclerosis (2002) (51)
Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. (1997) (51)
The effect of interferon beta-1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis (2000) (50)
Molecular mechanism underlying the impact of vitamin D on disease activity of MS (2014) (50)
Outcome measurement in multiple sclerosis: detection of clinically relevant improvement (2010) (50)
Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually‐edited SIENA and SIENAX (2007) (50)
Serum homocysteine levels in relation to clinical progression in multiple sclerosis (2008) (50)
Gender differences in multiple sclerosis: Cytokines and vitamin D (2009) (50)
Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. (2002) (49)
Innate production of interleukin‐10 and tumor necrosis factor affects the risk of multiple sclerosis (2000) (49)
Cerebrospinal fluid ATP metabolites in multiple sclerosis (2010) (48)
Short-term adaptation to a simple motor task: A physiological process preserved in multiple sclerosis (2009) (48)
Magnetization Transfer Ratio of the Spinal Cord in Multiple Sclerosis: Relationship to Atrophy and Neurologic Disability (2000) (47)
A study validating changes in the multiple sclerosis functional composite. (2002) (47)
Neutralising antibodies to interferon β during the treatment of multiple sclerosis (2003) (46)
Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)‐enhanced MRI to demonstrate diffuse inflammation in the normal‐appearing white matter (NAWM) of multiple sclerosis (MS) patients: An exploratory study (2009) (46)
Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. (1996) (46)
Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy (2003) (46)
Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients (2005) (46)
One year changes in disability in multiple sclerosis: neurological examination compared with patient self report (2003) (46)
Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components? (2010) (45)
Primary progressive multiple sclerosis diagnostic criteria: a reappraisal (2009) (45)
Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone (2002) (45)
Multislice T1 relaxation time measurements in the brain using IR‐EPI: Reproducibility, normal values, and histogram analysis in patients with multiple sclerosis (2003) (45)
Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI study (1998) (44)
Disease course heterogeneity and OCT in multiple sclerosis (2014) (44)
BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis (2011) (43)
Comparison of a conventional cardiac-triggered dual spin-echo and a fast STIR sequence in detection of spinal cord lesions in multiple sclerosis (2000) (43)
Motor evoked potential: A reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI (2007) (43)
Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis (2010) (43)
Contrasting responses to interferon β‐1b treatment in relapsing‐remitting multiple sclerosis: Does baseline interleukin‐12p35 messenger RNA predict the efficacy of treatment? (2000) (43)
Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study (2003) (43)
Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis (2007) (42)
Seasonal variation in immune measurements and MRI markers of disease activity in MS (2002) (42)
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development (2014) (42)
Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis (2006) (42)
Infusion-related hypersensitivity reactions during natalizumab treatment (2006) (42)
Neutralising antibodies to interferon β in multiple sclerosis (2007) (42)
Autoantibodies against alpha B-crystallin, a candidate autoantigen in multiple sclerosis, are part of a normal human immune repertoire (2006) (42)
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis (2010) (41)
N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry (2007) (41)
Magnetic Resonance Imaging of Epilepsy in Multiple Sclerosis: A Case Control Study. Implications for Treatment Trials with 4-Aminopyridine (1996) (41)
Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury (2001) (41)
The recognition, diagnosis and management of cerebral vasculitis: a European survey (2002) (41)
The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis. (2014) (41)
A glucocorticoid receptor gene haplotype (TthIII1/ER22/23EK/9beta) is associated with a more aggressive disease course in multiple sclerosis. (2009) (41)
Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis (2002) (40)
Increased visual impairment after exercise (Uhthoff's phenomenon) in multiple sclerosis: therapeutic possibilities. (1992) (40)
The role of disability and depression in cognitive functioning within 2 years after multiple sclerosis diagnosis (2008) (40)
Morphological features of MS lesions on FLAIR* at 7 T and their relation to patient characteristics (2014) (39)
A comparison of responsiveness indices in multiple sclerosis patients (1999) (39)
Assessment of JC virus DNA in blood and urine from natalizumab‐treated patients (2010) (39)
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course (2013) (39)
The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers (2005) (39)
Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization (2005) (38)
Psychological functioning in primary progressive versus secondary progressive multiple sclerosis. (1998) (38)
Interferon β-1b–neutralizing antibodies 5 years after clinically isolated syndrome (2011) (38)
No major association of A poE genotype with disease characteristics and MRI findings in multiple sclerosis (2004) (38)
Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped (2012) (38)
Sagittal MR of multiple sclerosis in the spinal cord: fast versus conventional spin-echo imaging. (1998) (37)
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. (2009) (37)
HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. (2009) (37)
Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS (2003) (37)
Cognition in MS correlates with resting-state oscillatory brain activity: An explorative MEG source-space study☆ (2013) (37)
Quantifying Progression of Multiple Sclerosis via Classification of Depth Videos (2014) (36)
The FAS−670 polymorphism influences susceptibility to multiple sclerosis (2002) (36)
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis (2010) (36)
Internet-based self-help treatment for depression in multiple sclerosis: study protocol of a randomized controlled trial (2012) (35)
Multiple Sclerosis: Clinical Challenges and Controversies (1997) (35)
Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. (2007) (35)
Costs and quality of life in multiple sclerosis in The Netherlands (2007) (35)
Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist (2004) (35)
The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment (2003) (35)
The search for responsive clinical endpoints in primary progressive multiple sclerosis (2009) (35)
Association between MRI parameters and the MS severity scale: a 12 year follow-up study (2009) (35)
Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS (2013) (34)
Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS (2010) (34)
A cluster randomised controlled trial on the efficacy of client-centred occupational therapy in multiple sclerosis: good process, poor outcome (2013) (34)
Evaluation of the visual system in multiple sclerosis: a comparative study of diagnostic tests (1992) (33)
Cardiovascular autonomic function in patients with relapsing remitting multiple sclerosis: a new surrogate marker of disease evolution? (1999) (33)
Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. (2010) (33)
A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility (2010) (33)
Growth‐associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis (2006) (33)
Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers (2010) (32)
Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis (2011) (32)
Patterns of Brain Magnetic Resonance Abnormalities on T2-Weighted Spin Echo Images in Clinical Subgroups of Multiple Sclerosis: A Large Cross-Sectional Study (1998) (32)
Cannabinoids in Multiple Sclerosis (2004) (32)
Minor myelin proteins can be majot targets for peripheral blood T cells from both multiple sclerosis patients and healthy subjects (1993) (31)
Progression in disability and regional grey matter atrophy in relapsing–remitting multiple sclerosis (2014) (31)
Ethics of placebo-controlled clinical trials in multiple sclerosis (2008) (31)
INTERMED: a measure of biopsychosocial case complexity: one year stability in Multiple Sclerosis patients. (2004) (31)
The physiological variation of the retinal nerve fiber layer thickness and macular volume in humans as assessed by spectral domain-optical coherence tomography. (2012) (31)
Pupillary light reflex latency in patients with multiple sclerosis. (1992) (31)
Multiple sclerosis functional composite: impact of reference population and interpretation of changes (2002) (31)
Multiple Sclerosis: The Guide to Treatment and Management (2012) (30)
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. (2007) (30)
Spinal cord magnetic resonance imaging in suspected multiple sclerosis (2000) (30)
Relation between objective and subjective measures of bladder dysfunction in multiple sclerosis (2004) (30)
Histone deacetylase gene variants predict brain volume changes in multiple sclerosis (2013) (30)
A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis (2007) (30)
αB-Crystallin genotype has impact on the multiple sclerosis phenotype (2003) (29)
Longitudinal follow-up of cardiovascular reflex tests in multiple sclerosis (1998) (29)
A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis (1996) (29)
Multiple sclerosis: immunological findings and possible implications for therapy (1992) (29)
Homocysteine in relation to cognitive performance in pathological and non-pathological conditions (2005) (29)
How similar are commonly combined criteria for EDSS progression in multiple sclerosis? (2006) (28)
Acute severe memory impairment as a presenting symptom of multiple sclerosis: a clinical case study with 3D double inversion recovery MR imaging (2010) (27)
Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes (2014) (27)
Analysis of CD27 surface expression on T cell subsets in MS patients and control individuals (1995) (27)
The challenge of follow-on biologics for treatment of multiple sclerosis (2009) (27)
The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis (2005) (27)
Cannabinoids in multiple sclerosis: do they have a therapeutic role? (2004) (26)
Vitality, perceived social support and disease activity determine the performance of social roles in recently diagnosed multiple sclerosis: a longitudinal analysis. (2008) (26)
Antibody‐mediated suppression of Vβ5.2/5.3+ T cells in multiple sclerosis: Results from an MRI‐monitored phase II clinical trial (2002) (26)
Is Chlamydia pneumoniae present in the central nervous system of multiple sclerosis patients? (2000) (26)
Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis (2001) (26)
Future clinical challenges in multiple sclerosis (2011) (26)
MR outcome parameters in multiple sclerosis: comparison of surface-based thresholding segmentation and magnetization transfer ratio histographic analysis in relation to disability (a preliminary note). (1998) (26)
Gene expression signatures: biomarkers toward diagnosing multiple sclerosis (2011) (26)
Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial. (1995) (26)
Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis (2005) (25)
Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis (2001) (25)
Lack of interferon‐beta bioactivity is associated with the occurrence of relapses in multiple sclerosis (2009) (25)
Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life (2006) (25)
Quantitative measurement of vibratory sense and temperature sense in patients with multiple sclerosis. (1992) (24)
Magnetic resonance imaging studies in multiple sclerosis twins. (1989) (24)
Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials (1997) (24)
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS (2011) (24)
Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. (2001) (24)
TNFα production by CD4+ T cells predicts long-term increase in lesion load on MRI in MS (2001) (24)
The impact of glucocorticoid receptor gene polymorphisms on glucocorticoid sensitivity is outweighted in patients with multiple sclerosis (2005) (24)
Rapid spontaneous resolution of an acute subdural hematoma. (1986) (24)
Using the Short Form-36 with Multiple Sclerosis Patients in Five Countries: A Cross-Cultural Comparison (1999) (24)
Clinical scales in progressive MS: predicting long-term disability (2012) (24)
The initial course of daily functioning in multiple sclerosis: a three-year follow-up study (2005) (24)
Observer agreement in the assessment of clinical signs in experimental allergic encephalomyelitis (1989) (23)
Multiple sclerosis therapy. A practical guide. (1995) (23)
The development of clinical activity in relapsing–remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood (2003) (23)
Spatiotemporal distribution of white matter lesions in relapsing–remitting and secondary progressive multiple sclerosis (2012) (23)
Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes (2013) (23)
Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy (2015) (22)
Validation and interpretation of the Dutch version of the Multiple Sclerosis Neuropsychological Screening Questionnaire (2012) (22)
Is Epstein–Barr virus present in the CNS of patients with MS? (2001) (22)
The treatment of multiple sclerosis: current and future. (1995) (22)
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis (2016) (22)
Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years (2006) (22)
Analysis of T cell receptor-gene rearrangement in T cells from the cerebrospinal fluid of patients with multiple sclerosis (1987) (21)
Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells (2001) (21)
Current trials in multiple sclerosis: established evidence and future hopes (2005) (21)
Glucocorticoid receptor gene polymorphisms associated with more aggressive disease phenotype in MS (2007) (21)
Polymorphisms in the genes encoding interferon-gamma and interferon-gamma receptors in multiple sclerosis. (2004) (21)
Glutamate gene polymorphisms predict brain volumes in multiple sclerosis (2013) (21)
Development of a Cognitive Behavioral Group Intervention Programme for Patients with Multiple Sclerosis: An Exploratory Study (2004) (21)
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency (2010) (21)
Interferon beta-1b treatment does not induce autoantibodies (2005) (20)
Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics? (2009) (20)
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome (2014) (20)
A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis (1996) (20)
Factor structure of the Disability and Impact Profile in patients with multiple sclerosis (2004) (20)
Gender-related association between the TGFB1+869 polymorphism and multiple sclerosis. (2004) (20)
Feasibility and outcome of a web-based self-help intervention for depressive symptoms in patients with multiple sclerosis: A pilot study (2012) (20)
Detecting clinically-relevant changes in progressive multiple sclerosis (2015) (20)
Relevance of IL7R genotype and mRNA expression in Dutch patients with multiple sclerosis (2011) (20)
The first 10 years with multiple sclerosis: the longitudinal course of daily functioning. (2013) (20)
Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS (2005) (20)
Disease progression in multiple sclerosis: combining physicians’ and patients’ perspectives? (2011) (20)
Reliability of Two Measures of Health-Related Quality of Life in Patients with Multiple Sclerosis (1998) (19)
The interleukin-1 gene family in multiple sclerosis susceptibility and disease course (2003) (19)
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome (2009) (19)
Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis (2015) (18)
Bench to Bedside and Beyond (2016) (18)
Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-β (2002) (18)
Client-centred therapy in multiple sclerosis: more intensive diagnostic evaluation and less intensive treatment. (2014) (17)
Th-cell modulation in multiple sclerosis. (1997) (17)
Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2. (1991) (17)
Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients (2006) (17)
Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis. (1998) (17)
Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of Interferon beta-1b in patients with Secondary Progressive Multiple Sclerosis (2005) (16)
How to use spinal cord magnetic resonance imaging in the McDonald diagnostic criteria for multiple sclerosis (2005) (16)
Multiple sclerosis: some possible therapeutic opportunities. (1993) (16)
Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI? (2014) (16)
Intracellular adhesion molecule‐1 polymorphisms and genetic susceptibility to multiple sclerosis: Additional data and meta‐analysis (2000) (16)
Physical and cognitive functioning after 3 years can be predicted using information from the diagnostic process in recently diagnosed multiple sclerosis. (2009) (16)
Diagnosing MS: recent guidelines and future goals focusing on magnetic resonance imaging. (2007) (15)
Treatment recommendations for interferon-β in multiple sclerosis (1999) (15)
Hypointense Lesions on T 1-Weighted Spin-Echo Magnetic Resonance Imaging Relation to Clinical Characteristics in Subgroups of Patients With Multiple Sclerosis (2001) (15)
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy (2015) (15)
Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis (2010) (15)
Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis (2006) (15)
BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis (2006) (14)
The therapeutic value of cannabinoids in MS: real or imaginary? (2004) (14)
Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients (2014) (14)
Interferon-β bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice (2009) (14)
Suppressive effect of glucocorticoids on TNF-α production is associated with their clinical effect in multiple sclerosis (2010) (14)
Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability (2008) (14)
Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study (2014) (14)
Cerebrospinal fluid cells in multiple sclerosis and other neurological diseases: an immunocytochemical study (2004) (14)
Clinical results from AFFIRM: A randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab in patients with relapsing multiple sclerosis (MS) (2005) (14)
Accuracy and interobserver variation in the interpretation of computed tomography in solitary brain lesions. (1990) (13)
Disappearance of multiple sclerosis lesions with severely prolonged T1 on images obtained by a FLAIR pulse sequence. (1996) (13)
Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression (2012) (13)
Functional defects in peripheral blood T cells of multiple sclerosis patients Diminished in vitro responsiveness in accessory cell dependent activation systems (1994) (13)
Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years (2008) (13)
Oral or intravenous methylprednisolone for acute relapses of MS? (1997) (13)
Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study (S41.004) (2012) (13)
Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis (2012) (13)
Performance of the Swanton multiple sclerosis criteria for dissemination in space (2010) (12)
A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome (2009) (12)
Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scales (2012) (12)
Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels (2004) (12)
Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study (2011) (12)
Treatment with depleting CD 4 monoclonal antibody results in a preferential loss of circul ; ating naive T cells but does not affect IFN-gamma secreting TH 1 cells in humans (1997) (12)
Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies (2009) (11)
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. (2008) (11)
Sensitivity of eye movement registration and visual evoked potentials in evaluation of therapy in patients with multiple sclerosis (1991) (11)
Cladribine treatment of multiple sclerosis (1994) (11)
Multiple sclerosis: incorporation of results of laboratory techniques in the diagnosis (1985) (11)
Classification of multiple sclerosis patients by latent class analysis of magnetic resonance imaging characteristics (2006) (11)
Genetic Correlations of Brain Lesion Distribution in Multiple Sclerosis: An Exploratory Study (2011) (11)
Proxy ratings from multiple sources: disagreement on the impact of multiple sclerosis on daily life (2008) (11)
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis (2016) (10)
Immunogenetics of chronic inflammatory and autoimmune diseases (2007) (10)
Statins for the treatment of multiple sclerosis: cautious hope (2004) (10)
No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up (2007) (10)
The therapeutic effect of bromocriptine on acute and chronic experimental allergic encephalomyelitis (1992) (10)
Neuromyelitis optica (Devic's syndrome): not always multiple sclerosis (1988) (10)
Study Design and Baseline Characteristics of the INFORMS Study: Fingolimod in Patients with Primary Progressive Multiple Sclerosis (P07.116) (2013) (9)
OPL099 Betaferon® in newly emerging multiple sclerosis for initial treatment (BENEFIT): First results (2005) (9)
Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales (2014) (9)
Determination of 4-aminopyridine in serum by solid-phase extraction and high-performance liquid chromatography. (1992) (9)
Opticospinal multiple sclerosis: a pathogenetically distinct form? (2004) (9)
Analysing the effect of candidate genes on complex traits: an application in multiple sclerosis (2006) (9)
Analyzing differences between patient and proxy on Patient Reported Outcomes in multiple sclerosis (2013) (9)
MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process (vol 11, pg 471, 2015) (2015) (9)
Multiple Sclerosis Therapy (1995) (8)
Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have? (2006) (8)
No evidence that polymorphisms of the vanishing white matter disease genes are risk factors in multiple sclerosis (2008) (8)
Early diagnosis of multiple sclerosis-still a challenge? (2008) (8)
Assessment of Disability in Multiple Sclerosis Using the Kinect-Camera System: A Proof-of-Concept Study (2014) (8)
The value of continuous intra-operative EEG monitoring during carotid endarterectomy (2005) (8)
Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results (2007) (8)
Double-blind randomized multicenter dose-comparison study of interferon-β-1a (AVONEX): rationale, design and baseline data (2001) (8)
Double-blind, placebo-controlled, MR monitored exploratory trial of chimeric anti-CD4 antibodies in MS. (1995) (8)
Improving function: a new treatment era for multiple sclerosis? (2009) (7)
Ocular comorbidity in multiple sclerosis (2003) (7)
Impact of early interferon beta-1b treatment on disease evolution over five years in patients with a first event suggestive of multiple sclerosis (2008) (7)
The size of the treatment effect: do patients and proxies agree? (2009) (7)
Assessing the quality of life of patients with multiple sclerosis (1997) (7)
Making a diagnosis in patients with an isolated spinal cord syndrome (1990) (7)
At the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities only (2008) (7)
Carotid endarterectomy: how does it work? A clinical and angiographic evaluation. (1986) (7)
Erratum: The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL (Journal of Neurology (2009) 256 (405-415) DOI: 10.1007/s00415-009-0093-1) (2009) (7)
HLA-DRB 1 * 1501 and Spinal Cord Magnetic Resonance Imaging Lesions in Multiple Sclerosis (2009) (7)
Polymorphisms in the genes encoding interferon-γ and interferon-γ receptors in multiple sclerosis (2004) (7)
8 year follow-up of the European study of Interferon beta-1b (EUSPMS) in secondary progressive MS (2004) (7)
The significance of in-situ Ia antigen expression in the pathogenesis of autoimmune central nervous system disease. (1993) (7)
Anti-myelin antibodies in multiple sclerosis: clinically useful? (2006) (7)
SEVERE CARDIAC FAILURE IN A PATIENT WITH MULTIPLE SCLEROSIS FOLLOWING LOW-DOSE MITOXANTRONE TREATMENT (2010) (6)
Effect of K+ channel blockers on the clinical course and histological features of experimental allergic encephalomyelitis (1994) (6)
Accumulation of hypointense lesions (“black holes”) on T1 weighted images of multiple sclerosis patients correlates with disease progression in secondary progressive MS patients (1995) (6)
The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee (2004) (6)
Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium-“enhanced” STIR imaging (2004) (6)
Erratum: Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy (Journal of the Neurological Sciences 184 (2001) (155-162) PII: S0022510X01004312) (2001) (6)
Choosing drug therapy for multiple sclerosis. An update. (1998) (5)
Association of APOE polymorphisms with disease severity in MS is limited to women (2004) (5)
The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions (2008) (5)
Multiple sclerosis: Should MR criteria for dissemination in time be less stringent (2004) (5)
IFN-beta1b augments glucocorticoid-induced suppression of tumor necrosis factor-alpha production by increasing the number of glucocorticoid receptors on a human monocytic cell line. (2001) (5)
Treatment with depleting anti-CD4 mAb deletes circulating naive T cells but does not affect IFN-γ secreting TH1 cells in man☆ (1997) (5)
Toward the use of proxy reports for estimating long-term patient-reported outcomes in multiple sclerosis (2015) (4)
OPL100 The effects of natalizumab on disability progression as measured by the Multiple Sclerosis Functional Composite (MSFC) and visual function in patients with relapsing MS (2005) (4)
Serum 25-hydroxyvitamin D concentrations among patients in BENEFIT predicts conversion to multiple sclerosis, MRI lesions, and brain volume loss (2012) (4)
A powerful tool in diagnosis and prognosis Spinal cord lesions in patients with clinically isolated syndrome : March 8 (4)
The effects of natalizumab on brain atrophy and cognitive function: results from the AFFIRM study (2006) (4)
The role of spinal cord imaging in the diagnosis of multiple sclerosis (2006) (4)
Cannabinoids and immune function. (2003) (4)
A commentary on steroid treatment in multiple sclerosis. (1991) (4)
The efficacy of natalizumab on magnetic resonance imaging (MRI) measures in patients with relapsing multiple sclerosis (MS): Results from the AFFIRM trial (2005) (4)
Low‐dose Cyclosporin A Induces Relapsing Experimental Allergic Encephalomyelitis in the Lewis Rat (1988) (4)
Antibodies to aquaporin-4 in patients with a clinically isolated syndrome: analysis from the BENEFIT study (2008) (4)
Diagnosis of multiple sclerosis. (2008) (4)
Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferon b therapy in multiple sclerosis (2011) (4)
Genome-wide RNA expression profiling in human grey and white matter tissue reveals a role for PSA-NCAM dysregulation in MS pathogenesis (2014) (4)
Long-term follow-up of suspected though unconfirmed MS (2008) (4)
Vitamin D as a predictor of multiple sclerosis activity and progression. (2013) (3)
Towards a European Network for Multiple Sclerosis Trials (ENMST) (2003) (3)
Proof of concept studies for tissue-protective agents in multiple sclerosis (2009) (3)
Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonb therapy in multiple sclerosis (2012) (3)
Cannabis Use in Multiple Sclerosis: Excited Interest (2003) (3)
Reply: To PMID 11456302. (2006) (3)
Choosing Drug Therapy for Multiple Sclerosis (1998) (3)
INTERMED: Temporal stability in a sample of MS patients (2004) (3)
No influence of KIF1B on neurodegenerative markers in multiple sclerosis (2011) (3)
A Computer-Based Screening Method for Distress in Patients With Multiple Sclerosis: A Feasibility Study (2014) (3)
Failure of sulfasalazine to influence experimental autoimmune encephalomyelitis (1991) (3)
A rare, treatable cause of relapsing encephalopathy in an MS patient on interferon beta therapy (2003) (3)
Effect of rimonabant on weight reduction and cardiovascular risk (2005) (3)
Interleukin-2 therapy does not exacerbate multiple sclerosis (1997) (3)
Predicting short-term disability progression in early MS : added value of MRI parameters (2011) (2)
Relevance of IL 7 R genotype and mRNA expression in Dutch patients with multiple sclerosis (2011) (2)
Longterm meningeal involvement as the only clinical manifestation of low grade malignant non-Hodgkin's lymphoma (1990) (2)
Glucocorticoid Receptor Gene Haplotype (TthIII1/ER22/23EK/9 beta) Is Associated with a More Aggressive Disease Course in Multiple Sclerosis (vol 94, pg 2110, 2009) (2009) (2)
Presence of Ia-positive cells in the central nervous system of the rat during various pathological conditions. (1987) (2)
Slower progression of Parkinson’s disease in patients treated with ropinirole compared with L-dopa: REAL-PET – a randomised controlled 18F-dopa PET study (2002) (2)
Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM (2013) (2)
4‐Aminopyridine in multiple sclerosis (1990) (2)
Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. (2007) (2)
Sustained Improvement in Physical Disability with Natalizumab in Patients with Relapsing Multiple Sclerosis (2009) (2)
A small heat shock protein serves as immunodominant T-cell antigen in MS-affected human myelin (1994) (2)
Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis (2012) (2)
Use of Anti‐Interferon Beta Antibody Measurements in Multiple Sclerosis (2010) (2)
Application of the revised version of the 2010 McDonald diagnostic criteria: retrospective comparison using the BEN-EFIT clinical study dataset (2012) (2)
New criteria for the diagnosis of multiple sclerosis (2005) (2)
Antibodies to aquaporin-4 in patients with a clinically isolated syndrome: analyses from the BENEFIT study (BEtaferon (R) in Newly Emerging multiple sclerosis For Initial Treatment) (2008) (2)
Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium‐enhanced MR images (1997) (2)
Natalizumab increases the proportion of patients free of clinical or MRI disease activity in relapsing multiple sclerosis (2008) (2)
The Expression of Ia Antigen in the Course of Acute and Relapsing Experimental Allergic Encephalomyelitis in the Lewis Rat (1990) (2)
Long-term effect of early treatment with interferon-beta-1b after a first clinical event suggestive of multiple sclerosis: 8-year observational extension of the phase 3 BENEFIT trial (2011) (2)
Interferon beta-16 delays progression of disability in secondary progressive multiple sclerosis — results of the european multicenter study (1998) (2)
Upside down Guillain Barré syndrome (1991) (2)
Mononuclear cell subpopulations in cerebrospinal fluid (1986) (2)
Interferon-beta-1b reduces development of T1 black holes on MRI in secondary progressive multiple sclerosis (2000) (2)
MRI monitoring of cerebral atrophy during a placebo-controlled trial of interferon-beta-1b in secondary progressive multiple sclerosis (2000) (2)
Safety and tolerability results of a phase 2b extension study of the novel oral fumarate BG00012 for the treatment of relapsing-remitting multiple sclerosis (2007) (2)
Early Initiation of Interferon Beta-1b after a First Clinical Event Suggestive of Multiple Sclerosis: Clinical Outcomes and Use of Disease-Modifying Therapy from the BENEFIT Extension Study (PD5.002) (2012) (2)
Cytokines And Multiple Sclerosis (1997) (2)
Prognostic relevance of antimyelin antibodies for progression to multiple sclerosis after a first demyelinating event: results from the BENEFIT study (2006) (2)
4-31-17 MRI protocol for the European trial of beta interferon-1b in secondary progressive multiple sclerosis (1997) (2)
The efficacy of BG00012 in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2B study (2008) (2)
Diagnosis and Management of Neuromyelitis Optica (2011) (2)
[Copolymer 1 in the treatment of multiple sclerosis]. (1994) (2)
Relationship between Timed 25-Foot Walk Walking Speed and Health-Related Quality of Life in AFFIRM and SENTINEL (P07.097) (2012) (2)
A Cochrane review of recombinant interferons trials in relapsing multiple sclerosis (2001) (1)
Betaferon(R) in newly emerging multiple sclerosis for initial treatment (BENEFIT): Clinical outcomes (2006) (1)
Compléments : Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects (2012) (1)
Baseline magnetic resonance imaging predictors for conversion to clinically definite multiple sclerosis and McDonald multiple sclerosis, based on integrated 3-year data from the BENEFIT study (2008) (1)
Effects of natalizumab treatment on sustained improvement in physical disability and quality of life in patients with relapsing multiple sclerosis (2009) (1)
FMRI of the visual cortex: A pilot study in patients with optic neuritis using monocular stimulation (1997) (1)
Baseline characteristics and patient adherence in the BENEFIT study (2005) (1)
Contribution of CSF to the Diagnosis of McDonald MS: Retrospective Analysis in the BENEFIT Study (P03.235) (2013) (1)
Predicting the On-Study Relapse Rate for Multiple Sclerosis Patients in Clinical Trials (2005) (1)
Natalizumab to treat multiple sclerosis (2011) (1)
Clinical and conventional MRI features of non-disabling MS. A large-scale, multicentre, multinational, cross-sectional study (2008) (1)
[New diagnostic criteria for multiple sclerosis in clinical practice]. (2004) (1)
Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain (1994) (1)
Safety profile of BG00012, all oral formulation of dimethyl fumarate for patients with relapsing MS (2008) (1)
Improved white matter integrity with natalizumab treatment in multiple sclerosis (2014) (1)
Corticosteroids and bone mass. (1990) (1)
Betaferon (R)/betaseron (R) in newly emerging multiple sclerosis for initial treatment (benefit): Effects of early vs. delayed treatment with interferon beta-1B (2007) (1)
Natalizumab improves health-related quality of life in patients with relapsing multiple sclerosis (2006) (1)
Erratum to “Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy” [J. Neurol. Sci. 184 (2001) 155–162] (2001) (1)
Short communication In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology (2005) (1)
Intermediate uveitis and polyneuropathy in an elderly patient due to sarcoidosis (1999) (1)
Reply (2006) (1)
Neuroprotective Treatment in Primary Progressive Multiple Sclerosis: a Phase I/II Study with Riluzole (2004) (1)
A Dutch window into the development of a two tier healthcare system (2010) (1)
The effects of natalizumab on disability progression in the AFFIRM study: correlation between changes in Multiple Sclerosis Functional Composite and Expanded Disability Status Scale scores (2005) (1)
The incidence and clinical significance of antibodies to natalizumab over 2 years of treatment in patients with multiple sclerosis (2006) (1)
MRI versus clinical relapses as a measure of disease activity in MS (2000) (1)
[Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness]. (2004) (1)
Natalizumab improves disability on the Multiple Sclerosis Functional Composite in a randomised, double-blind, placebo-controlled study of patients with relapsing multiple sclerosis (2009) (1)
Complete clinical and magnetic resonance imaging response with natalizumab in multiple sclerosis (2008) (1)
Effects of interferon beta-1 b on cognitive performance in patients with a first event suggestive of multiple (2012) (1)
Natalizumab increases the proportion of disease-free patients in relapsing multiple sclerosis (2008) (1)
Pain in patients with multiple sclerosis: Effects of natalizumab (2008) (1)
The BENEFIT studies: adherence, tolerability and quality of life with Betaferon((R)) treatment after a first event suggestive of multiple sclerosis (2008) (1)
Clinical trials in neurology: Are rating scales stable across European countries? (2004) (1)
Neutralising antibodies do not affect efficacy of interferon beta-1b: further analysis of the BEtaferon (R) in Newly Emerging multiple sclerosis For Initial Treatment study (BENEFIT) (2008) (1)
Predictors of disease activity in patients with clinically isolated syndrome (CIS) treated with interferon beta 1b in the BENEFIT trial (2013) (0)
Application of Lesion Probability Maps to predict progression in primary-progressive multiple sclerosis: a 10-year multi- centre study (2009) (0)
Abstracts from PACTRIMS (2013) (0)
Early therapy with IFNB-1b started at the first event suggestive of MS reduces the evolution of persistent T1 hypointensities on brain MRI (2012) (0)
Comparison Between Impact Factors and Citations in Evidence-Based Practice Guidelines (2017) (0)
Late Breaking News (1976) (0)
OPL114 The effects of baseline disease activity on magnetic resonance imaging (MRI) outcomes in the AFFIRM study (2005) (0)
Impact of neurodegeneration and other pathology on clinical dysfunction in multiple sclerosis (2016) (0)
Klinimetrische evaluatie bij multiple sclerose (MS) en determinanten voor prognose (1997) (0)
Multiple Sclerosis and 4-Aminopyridine (1991) (0)
A 10-year follow-up of the European multicenter trial of interferon β1 b in secondary-progressive multiple sclerosis (2016) (0)
Slowing of cerebral atrophy after year 1 in a placebo-controlled trial of interferon beta 1b in secondary progressive multiple sclerosis (2007) (0)
Chapter 4 . 2 Pathway analysis of microRNA expression in multiple sclerosis lesions (2012) (0)
Increase of uric acid and purine compounds in serum of multiple sclerosis patients (2009) (0)
DEPARTMENT OF ERROR (1995) (0)
Multiple sclerosis: incorporation of results of laboratory techniques in the diagnosis. (1986) (0)
Echoes of Pathology. Quantitative Magnetic Resonance Studies of the Normal-Appearing White and Gray Matter in Multiple Sclerosis (2000) (0)
Subtle blood brain barrier leakage in non-enhancing lesions in relapsing multiple sclerosis: multi-centre study of patients in a therapeutic trial (2005) (0)
UvA-DARE ( Digital Academic Repository ) Immune functions in untreated and treated multiple sclerosis patients (2012) (0)
Effect of IS + channel blockers on the clinical course and histological features of experimental allergic encephalomyelitis (0)
Adrenal function after corticosteroid treatment in MS (1991) (0)
Cladribine treatment of multiple sclerosis. (1994) (0)
Natalizumab reduces loss of visual function in patients with relapsing multiple sclerosis (2006) (0)
The clinical value of magnetic resonance imaging for the diagnosis of multiple sclerosis (2018) (0)
Liquor bank for multiple sclerosis (2000) (0)
What does ( quantitative ) MRI of the MS cortical gray matter measure ? A post mortem imaging exploration . (2009) (0)
Chapter 8. Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis (2008) (0)
Oral session 16—Multiple sclerosis (4) (2005) (0)
Introduction (2007) (0)
Molecular dissection of the role of vitamin D in determining multiple sclerosis activity (2013) (0)
Brain atrophy in MS: long-term prognostic value (2011) (0)
Therapeutic Strategies in Multiple Sclerosis: The Value of Plasma Exchange (1991) (0)
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2007) (0)
The incidence and clinical significance of antibodies to natalizumab: 2-year results from the AFFIRM study (2005) (0)
Natalizumab in relapsing multiple sclerosis: appropriate patient selection, management guidelines, and a diagnostic algorithm for the differential diagnosis of new neurologic signs or symptoms (2006) (0)
Periodic Fluctuations in Cerebrospinal Fluid Mononuclear Cells (1987) (0)
Impaired energy metabolism and increased lipid peroxidation in multiple sclerosis (2006) (0)
Appearance and Distribution of Macrophages in the Central Nervous System of Lewis Rats with Acute Experimental Allergic Encephalomyelitis: An Immunohistochemical Study (1987) (0)
The effect of natalizumab on brain atrophy and its relationship with cognitive function in multiple sclerosis (2006) (0)
T2 lesion location really matters: a 10-year follow-up study in primary-progressive MS (2017) (0)
Sa.32. The Immunogenicity of Natalizumab in Patients with Multiple Sclerosis (2006) (0)
Other immunomodulatory therapies in multiple sclerosis. (1997) (0)
7 Tesla 3D-MP-FLAIR and 3D-MP-DIR: Lesion Detection in Multiple Sclerosis (2010) (0)
Chapter 2 . 1 Reduced biological activity of recombinant IFN-β and treatment response IFN-β bioactivity measurement in MS : feasibility for routine clinical practice (2014) (0)
Chapter 2 . 1 Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis (2011) (0)
A 1-year serial clinical and MRI study of primary progressive multiple sclerosis (1970) (0)
Proxy measurements in MS: does patient's cognitive impairment influence patient-proxy agreement on disease impact? (2007) (0)
Treating Systematic Errors in Multiple Sclerosis Data (2005) (0)
Letter to the Editor (2004) (0)
Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis (2011) (0)
FP33-WE-03 Effects of natalizumab treatment on sustained improvement in physical disability and quality of life in patients with relapsing multiple sclerosis (2009) (0)
Trial design and baseline data of the INFORMS (fingolimod in patients with primary progressive multiple sclerosis) study (2012) (0)
[Treatment of multiple sclerosis using recombinant interferon-beta]. (1994) (0)
Reply (2006) (0)
Book Review / News Item / Erratum (1987) (0)
Longitudinal proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of MS on daily life over a period of two years (2006) (0)
Comparison of 4 putative MR imaging marker of matrixdestruction in MS plaques (1995) (0)
IL-1ra gene polymorphism is associated with genetic susceptibility to ulcerative colitis and multiple sclerosis (1996) (0)
“It’s not what you look at that matters, it’s what you see.” (2015) (0)
Long Term Impact of Early Initiation of Interferon beta-1b after a First Clinical Event Suggestive of Multiple Sclerosis: Additional Relapse Rate, EDSS, and MSSS Analyses after 8 Years (P07.117) (2013) (0)
Sunday 31 August Monday 1 September Tuesday 2 September (2003) (0)
Expression of cytokine mRNA in relation to clinical disease parameters in MS patients (1998) (0)
Immuunmodulerende medicatie bij multiple sclerose (2007) (0)
Cerebrospinal fluid adenosine triphospate metabolites in multiple sclerosis (2009) (0)
The BENEFIT study: characteristics of patients with potentially benign multiple sclerosis (2007) (0)
The Clinical Meaning ofWalking Speed asMeasured by the Timed 25-FootWalk in PatientsWithMultiple Sclerosis (2014) (0)
The use of a quantitative PCR to study the role of cytokines in multiple sclerosis (1997) (0)
Reply (2011) (0)
The effects of natalizumab on disability and health-related quality of life in patients with relapsing MS (2006) (0)
The effects of natalizumab monotherapy on multiple measures of disability progression in MS patients (2006) (0)
Magnetic resonance imaging studies inmultiple sclerosis twins (1989) (0)
MRI Predictors for disability at 5 years after the diagnosis of MS (2011) (0)
Direct and indirect process in the quantification of cerebral atrophy in MS Results of a longitudinal study over 5.5 years (2009) (0)
Treating clinically isolated syndromes suggestive of MS – Authors' reply (2007) (0)
Letter to the editor (1986) (0)
study resonance venography and flow-quantification drainage with multiple sclerosis : a magnetic No association of abnormal cranial venous (0)
[Treatment of trigeminal neuralgia and hemifacial spasm: another viewpoint]. (1984) (0)
[Clinical testing of the treatment effect of interferon-beta Ia and Ib in multiple sclerosis]. (1996) (0)
The effect of linomide on gadolinium-enhancing lesions in multiple sclerosis (1998) (0)
Low-dose cyclosporin a induces relapsing EAE in the lewis rat (1987) (0)
Analysis of neutralising antibodies in the Betaferon (R) in newly emerging multiple sclerosis for initial treatment (BENEFIT) study (2006) (0)
Multiparametric MRI assessment of brain and cord damage in primary progressive multiple sclerosis: a large-scale, multicentre study (2006) (0)
Interferon-&bgr;1b in the treatment of secondary progressive MS: Impact on quality of life (2001) (0)
Multiple sclerosis (MS) and 1,25-dihydroxyvitamin D serum levels (2003) (0)
Magnetic resonance imaging results from AFFIRM: a randomised controlled trial of natalizumab in patients with relapsing multiple sclerosis (2005) (0)
Interobserver variation and accuracy in the interpretation of computer tomography in solitary supratentorial brain lesions Scientific meeting of the Netherlands Society of Neurology, held in Amsterdam, 22nd of April 1989 (1989) (0)
Scientific meeting of the Amsterdamsche Neurologenvereeniging, held in Amsterdam, 2nd April 1987 (1987) (0)
Betaferon(R) in newly emerging multiple sclerosis for initial treatment (BENEFIT): Safety, tolerability, and adherence (2006) (0)
[Current developments in the area of multiple sclerosis]. (1994) (0)
Reply (2011) (0)
Proposal for a morphologic classification of atypical idiopathic inflammatory demyelinating lesions of the brain based on conventional magnetic resonance imaging (2006) (0)
Monthly screening for neuropsychological impairment in multiple sclerosis (2007) (0)
Drs. Polman and Rudick reply [4] (2006) (0)
[Alemtuzumab in early multiple sclerosis]. (2009) (0)
Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study (2015) (0)
A randomised, placebo-controlled phase II trial of a novel oral single-agent fumarate therapy, BG00012, in patients with relapsing-remitting multiple sclerosis (2005) (0)
[Immunomodulatory therapy in multiple sclerosis]. (2007) (0)
Rna profiling in grey and white matter tissue yields clues towards multiple sclerosis etiology (2013) (0)
Lymphocyte Subpopulations in Cerebrospinal Fluid: Multiple Sclerosis and Other Neurological Disease Categories (1987) (0)
Clinical and conventional magnetic resonance imaging features of non-disabling multiple sclerosis: a large-scale, multicenter, multinational, cross-sectional study (2008) (0)
Neutraliserende antistoffen bij multiple sclerose (2009) (0)
Benefit 11: Long-term follow-up study of patients with clinically isolated syndrome treated with interferon beta-1b (2013) (0)
Genetic- and biomarkers for multiple sclerosis as indicators for pathogenesis and therapeutic response (2008) (0)
P2.57: Modelling Time to Progression in Multiple Sclerosis (2004) (0)
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci | NOVA. The University of Newcastle's Digital Repository (2011) (0)
Survival in a Transgenic Model of FALS Is Independent of iNOS Expression (2001) (0)
Elevated levels of the T-cell activation antigen soluble CD27 in CSF of multiple sclerosis patients (1991) (0)
The immunogenicity of natalizumab in patients with multiple sclerosis: Results from the AFFIRM study (2007) (0)
Cytotoxic immune responses mediated by monoclonal antibodies in MS: incorrectly dismissed as ineffective? (2007) (0)
Quantitative functional measures in MS: what is a reliable change? (2002) (0)
The relationship between disease severity and health-related quality of life in patients with relapsing multiple sclerosis (2006) (0)
GENDER EFFECTS ON ATROPHY IN MS : COGNITIVE IMPLICATIONS (2009) (0)
IRF 5 gene variants and pharmacologi al and clinical outcome of IFN-β therapy in MS (2014) (0)
IRF 5 gene variants and pharmacologi al and clinical outcome of IFN-β therapy in MS (2014) (0)
Grey Matters! MR imaging and hispathology studies of the grey matter in multiple sclerosis (2001) (0)
Individual and longitudinal evaluation of overproduction of free immunoglubulin light chains as a simple contribution to MS differential diagnosis (1994) (0)
Chapter 38. Cerebral Vasculitis (2008) (0)
Magnetic resonance imaging in multiple sclerosis twins Scientific meeting of the Netherlands Society of Neurology, held in Amsterdam, 22nd of April 1989 (1989) (0)
Spatial localisation of lesions predicts clinical deterioration in primary progressive multiple sclerosis: a 10-year multi-centre study (2009) (0)
Impact of sustained disability progression and relapses on visual outcomes in the AFFIRM trial (2007) (0)
The effect of the 21-aminosteroid U74006F on the clinical course of acute experimental allergic encephalomyelitis (1996) (0)
Analysis of CD27 surface expression on T-cell subsets in MS patients (1994) (0)
Intrathecal antibodies to neurofilament light (NF-L) correlate with MRI markers of axonal loss (2002) (0)
IL-1 RA gene polymorphism is associated with genetic susceptibility to multiple sclerosis (1995) (0)
Natalizumab in multiple sclerosis (2007) (0)
Functional defects in peripheral blood T cells of multiple sclerosis (MS) patients (1994) (0)
Prognostic relevance of antimyelin antibodies for the progression to multiple sclerosis after a first demyelinating event: Results of the BENEFIT trial (2006) (0)
The effect of natalizumab on brain atrophy in patients with relapsing multiple sclerosis: 2-year results from the AFFIRM study (2005) (0)
Multiple sclerose (MS) en 1,25-dihydroxyvitamine D spiegels (2003) (0)
Reply: Cerebrospinal fluid analysis in the 2010 revised McDonald's Multiple Sclerosis Diangostic Criteria (2011) (0)
Clinimetric evaluation in multiple sclerosis (MS) and determinants of prognosis (1997) (0)
Relating functional reorganisation in multiple sclerosis to clinical measures in a multi-centre study (2006) (0)
Scientific meeting of the Amsterdamsche neurologenvereeniging held in Amsterdam, 3rd April 1986 (1987) (0)
[Interferon beta-1b now also for the relapsing progressive form of multiple sclerosis?]. (1999) (0)
Sample sizes for brain atrophy outcome measures in clinical trials for secondary progressive multiple sclerosis (2008) (0)
MxA mRNA level predicts relapses in a prospective cohort of early MS patients (2009) (0)
Neutralising Antibodies to Interferon Β Authors' Reply (0)
Early rate of ventricular enlargement predicts long-term clinical outcome in multiple sclerosis (2009) (0)
Validation of the clinical classification scheme using MRI in the BENEFIT Study (2005) (0)
Betaferon(R) in newly emerging multiple sclerosis for initial treatment (BENEFIT): Subgroup analysis (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Christopher H. Polman?

Christopher H. Polman is affiliated with the following schools:

Vrije Universiteit Amsterdam

Christopher H. Polman's Academic­Influence.com Rankings

Why Is Christopher H. Polman Influential?

Christopher H. Polman's Published Works

Published Works

What Schools Are Affiliated With Christopher H. Polman?

Christopher H. Polman's AcademicInfluence.com Rankings